Skip to main content
. 2022 May 10;53:102331. doi: 10.1016/j.redox.2022.102331

Fig. 5.

Fig. 5

CBS is upregulated in human breast cancer and correlates with worse clinical prognosis. A) Immunohistochemical staining of a tissue microarray of 60 human breast cancer samples. Data are presented as mean ​± ​SD of CBS staining. ∗p ​< ​0.05 shows significantly higher tumoral CBS levels compared to normal tissue. The panel was redrawn from data presented in Ref. [62]. B) Representative western blot, detecting CBS in-patient derived breast cancer tissues and matched normal breast tissues (n = 5). The panel was redrawn from data presented in Ref. [63]. C) Cystathionine levels in patient derived breast tumor and normal breast tissues (n ​= ​5). Data are represented as mean ​± ​SEM from three independent experiments, ∗p ​< ​0.05. The panel was redrawn from data presented in Ref. [63]. D) CBS overexpression in basal-like breast cancer. Correlation of CBS mRNA and protein levels in 45 tumors from the Oslo 2 cohort. The panel was redrawn from data presented in Ref. [64]. E) Survival curve showing the impact of CBS expression on overall survival in invasive breast carcinoma from the BRCA dataset showing a trend for better survival in low-CBS-expressing patients. The panel was redrawn from data presented in Ref. [55]. F) Survival curves showing the impact of CBS expression on overall survival in breast cancer from Atlas database (https://www.proteinatlas.org). ∗p ​< ​0.05 shows significantly better survival in low-CBS-expressing patients.